No abstract

No abstract

Background: Glioblastoma (GBM) is the most common and fatal primary brain tumor in adults. Therefore, there is interest in conducting clinical trials of experimental treatments on patients with GBM, where patients with history of cancer are usually excluded. This practice can affect clinical trials accrual and limit potential therapeutic options for this population. The rationale behind this exclusion is that a history of malignancy could potentially interfere with the study outcomes. However, little is known about its real impact on survival of subsequent GBM. Methods: We used the SEER database of the National Cancer Institute to review patients with GBM diagnosed between 1973 and 2014. We calculated the overall and GBM-specific survival of these patients using unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models. Results: Of the 51,158 GBM patients who were reviewed, 3076 had a prior malignancy. Unadjusted Kaplan-Meier test showed worse overall and GBM-specific survival with patients who had a prior history. However, after adjusting for multiple factors using cox regression models, a prior history was not associated with any significant difference in both overall and GBM-specific survival (HR ¼ 1.025 95% CI ¼ .986-1.066, P ¼ .213 and HR ¼ 1.005 95% CI ¼ .963 -1.049, P¼ .810, respectively). Conclusions: These results should be taken into consideration when putting inclusion/ exclusion criteria for GBM clinical trials. Legal entity responsible for the study: Individual group Funding: None Disclosure: All authors have declared no conflicts of interest.119O Mismatch repair deficiency (MMRD) and PD-L1 expression in high grade glioma (HGG) patients from Siloam Hospital Jakarta Indonesia